abs379.txt	objectives		to	model	the	cost-effectiveness	of	a	biomarker-based	approach	toselect	patients	for	neoadjuvant	chemotherapy	(nac)	before	radical	cystectomy	(rc)in	muscle-invasive	bladder	cancer	(mibc)	and	methods	we	obtained	data	from	most	recent	clinical	studies	onpatients	with	locally	advanced	mibc	treated	by	rc	including	stage	distributions	overall	survival	(os)	estimates	associated	costs	utilisation/response	tonac	additionally	estimated	putative	efficacy	three	biomarkers	nac	dna-repair	gene	panel	[ataxia	telangiectasia	mutated(atm)	retinoblastoma	1	(rb1)	fanconi	anaemia	complementation	group	c(fancc)]	excision	repair	cross-complementation	2	(ercc2)	ribonucleicacid	(rna)	subtypes	decision	analysis	was	developed	evaluate	thecost-effectiveness	approaches	select	fornac	comparison	included	alone	unselected	plus	based	on	aforementioned	results	panel-based	mostcost-effective	strategy	(mean	os	3	14	years	$31	482/life	year)	under	thisapproach	38%	would	undergo	about	twice	number	who	arecurrently	receiving	such	an	improve	mean	5	6	4	months	compared	hypothetical	scenario	where	allpatients	received	current	utilisation	respectively	conclusions	identify	shouldundergo	more	cost-effective	than	use	or	asfurther	becomes	available	may	serve	as	basis	forincorporating	into	making
